Found: 9
Select item for more details and to access through your institution.
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].
- Published in:
- International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
- Published in:
- International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
- By:
- Publication type:
- Article
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 3, p. 499, doi. 10.1007/s00280-021-04296-0
- By:
- Publication type:
- Article
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin<sup>®</sup>), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 8, p. 1096, doi. 10.1002/jcph.1855
- By:
- Publication type:
- Article
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 5, p. 702, doi. 10.1002/jcph.1362
- By:
- Publication type:
- Article